Mi SciELO
Servicios personalizadosServicios Personalizados
Revista
Articulo
Español (pdf)
Articulo en XML
Referencias del artículo
Traducción automática
Enviar articulo por emailIndicadores
Citado por SciELO 
Accesos
Links relacionados
Citado por Google 
Similares en
SciELO 
Similares en Google
Compartir
Permalink
Ars Pharmaceutica (Internet)
versión On-line ISSN 2340-9894
Resumen
GOODARZI, Rezvan et al. Estudio comparativo de las actividades in vitro de productos comerciales de polimixina B sobre Pseudomonas aeruginosa aislada de pacientes hospitalizados. Ars Pharm [online]. 2021, vol.62, n.3, pp.270-279. Epub 27-Sep-2021. ISSN 2340-9894. https://dx.doi.org/10.30827/ars.v62i3.17851.
Introduction:
Polymyxin B has been applied as one of the last-resort antibiotics for the treatment of multidrug resistance among Gram-negative bacterial infections. Due to side effects such as renal toxicity, the use of polymyxin is associated with limitations. The present study evaluates in vitro antibacterial activity of a number of polymyxin B commercial products against Pseudomonas aeruginosa.
Methods:
This study included 63 non-duplicated P. aeruginosa isolates examined for in vitro polymyxin B susceptibility testing using the following powder disks: polymyxin B sulfate, otosporin, Poly-Mxb, and Myxacort. MIC50 and MIC90 have also been identified for polymyxin B antibiotics.
Results:
Myxacort had functional activity against most P. aeruginosa isolates, and only seven isolates had a relatively high MIC. The activities of Poly-MXb and Myxacort were the same as otosporin.
Conclusions:
Our findings revealed that the national generic polymyxin B product (Myxacort), and two external products (Otosporin, Poly-MXb) are similar in terms of microbiological activity.
Palabras clave : Pseudomonas aeruginosa; Polymyxin B products; Broth microdilution method.
